JP6329370B2 - 呼吸器系ウイルスによる疾患の同時診断キット - Google Patents
呼吸器系ウイルスによる疾患の同時診断キット Download PDFInfo
- Publication number
- JP6329370B2 JP6329370B2 JP2013554403A JP2013554403A JP6329370B2 JP 6329370 B2 JP6329370 B2 JP 6329370B2 JP 2013554403 A JP2013554403 A JP 2013554403A JP 2013554403 A JP2013554403 A JP 2013554403A JP 6329370 B2 JP6329370 B2 JP 6329370B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- gene
- virus
- nos
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000700605 Viruses Species 0.000 title claims description 104
- 230000000241 respiratory effect Effects 0.000 title claims description 52
- 238000003745 diagnosis Methods 0.000 title claims description 20
- 201000010099 disease Diseases 0.000 title claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 18
- 239000000523 sample Substances 0.000 claims description 60
- 239000002773 nucleotide Substances 0.000 claims description 38
- 125000003729 nucleotide group Chemical group 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 28
- 238000003753 real-time PCR Methods 0.000 claims description 10
- 102100034343 Integrase Human genes 0.000 claims description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 6
- 102000004167 Ribonuclease P Human genes 0.000 claims description 5
- 108090000621 Ribonuclease P Proteins 0.000 claims description 5
- 108010006785 Taq Polymerase Proteins 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 description 82
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 38
- 108091028043 Nucleic acid sequence Proteins 0.000 description 26
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 25
- 238000000034 method Methods 0.000 description 22
- 102000011931 Nucleoproteins Human genes 0.000 description 18
- 108010061100 Nucleoproteins Proteins 0.000 description 18
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 14
- 108020001507 fusion proteins Proteins 0.000 description 13
- 101710154606 Hemagglutinin Proteins 0.000 description 11
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 11
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 11
- 101710176177 Protein A56 Proteins 0.000 description 11
- 239000000185 hemagglutinin Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 241000711467 Human coronavirus 229E Species 0.000 description 9
- 241000482741 Human coronavirus NL63 Species 0.000 description 9
- 241001428935 Human coronavirus OC43 Species 0.000 description 9
- 241000351643 Metapneumovirus Species 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 241000124740 Bocaparvovirus Species 0.000 description 8
- 241000712431 Influenza A virus Species 0.000 description 8
- 241000713196 Influenza B virus Species 0.000 description 8
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 7
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 7
- 108010076039 Polyproteins Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical group 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241001325464 Rhinovirus A Species 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 208000023504 respiratory system disease Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- 241000709661 Enterovirus Species 0.000 description 3
- 101710094396 Hexon protein Proteins 0.000 description 3
- 241001325459 Rhinovirus B Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 241001139982 Rhinovirus C Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000039 congener Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000007403 mPCR Methods 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- -1 phosphotriester Chemical compound 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 101900234398 Influenza B virus Hemagglutinin Proteins 0.000 description 1
- 241000702377 Inovirus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Description
鼻咽頭の吸引物或いはスワブ(swab)検体(NPS(Nasopharyngeal swabs)、NS(Nasla swabs)、TS(Throat swabs)、NA(Nasal aspirates))を対象として14種の呼吸器系ウイルスの検出及び区分を行うためのプライマー及びプローブを製作した。
本発明者は、コロナウイルス229Eの核タンパク質(N)遺伝子を増幅させることが可能な配列番号1及び2の塩基配列を有するプライマー、コロナウイルスOC43の核タンパク質(N)遺伝子を増幅させることが可能な配列番号3及び4の塩基配列を有するプライマー、コロナウイルスNL63のポリタンパク質(1a)遺伝子を増幅させることが可能な配列番号5及び6の塩基配列を有するプライマー、パラインフルエンザウイルス1のヘマグルチニン−ノイラミニダーゼ(HN)遺伝子を増幅させることが可能な配列番号7及び8の塩基配列を有するプライマー、パラインフルエンザウイルス2のヘマグルチニン−ノイラミニダーゼ(HN)遺伝子を増幅させることが可能な配列番号9及び10の塩基配列を有するプライマー、パラインフルエンザウイルス3のヘマグルチニン−ノイラミニダーゼ(HN)遺伝子を増幅させることが可能な配列番号11及び12の塩基配列を有するプライマー、A型インフルエンザウイルスの基質タンパク質(M)遺伝子を増幅させることが可能な配列番号13及び14の塩基配列を有するプライマー、RNase Pを標的とする内部対照群であって、RNA抽出過程の有効性に対する判断基準を提供する配列番号15及び16の塩基配列を有するプライマー、B型インフルエンザウイルスのヘマグルチニン(HA)遺伝子を増幅させることが可能な配列番号17及び18の塩基配列を有するプライマー、RsウイルスA型の融合タンパク質遺伝子を増幅させることが可能な配列番号19及び20の塩基配列を有するプライマー、RsウイルスB型の融合タンパク質遺伝子を増幅させることが可能な配列番号21及び22の塩基配列を有するプライマー、アデノウイルスのヘキソンタンパク質遺伝子を増幅させることが可能な配列番号25及び26の塩基配列を有するプライマー、ライノーウイルスA、B、Cの5’UTRを増幅させることが可能な配列番号27及び31の塩基配列を有するプライマー、メタニューモウイルスの核タンパク質(N)遺伝子を増幅させることが可能な配列番号23及び24の塩基配列を有するプライマー、及びボカウイルスのNP(nucleocapsid protein)遺伝子、VP(Viral protein)遺伝子を増幅させることが可能な配列番号32及び33の塩基配列を有するプライマーを通常の方法を用いてそれぞれ作製した(表1参照)。
本発明者らは、コロナウイルス229Eの核タンパク質(N)遺伝子を検出することが可能な配列番号34の塩基配列を有するプローブ、コロナウイルスOC43の核タンパク質(N)遺伝子を検出することが可能な配列番号35の塩基配列を有するプローブ、コロナウイルスNL63のポリタンパク質(1a)遺伝子を検出することが可能な配列番号36の塩基配列を有するプローブ、パラインフルエンザウイルス1のヘマグルチニン−ノイラミニダーゼ(HN)遺伝子を検出することが可能な配列番号37の塩基配列を有するプローブ、パラインフルエンザウイルス2のヘマグルチニン−ノイラミニダーゼ(HN)遺伝子を検出することが可能な配列番号38の塩基配列を有するプローブ、パラインフルエンザウイルス3のヘマグルチニン−ノイラミニダーゼ(HN)遺伝子を検出することが可能な配列番号39の塩基配列を有するプローブ、A型インフルエンザウイルスの基質タンパク質(M)遺伝子を検出することが可能な配列番号40の塩基配列を有するプローブ、内部対照群として、RNase Pを検出することが可能な配列番号41の塩基配列を有するプローブ、B型インフルエンザウイルスのヘマグルチニン(HA)遺伝子を検出することが可能な配列番号42の塩基配列を有するプローブ、RsウイルスA型の融合タンパク質遺伝子を検出することが可能な配列番号43の塩基配列を有するプローブ、RsウイルスB型の融合タンパク質遺伝子を検出することが可能な配列番号44の塩基配列を有するプローブ、メタニューモウイルスの核タンパク質(N)遺伝子を検出することが可能な配列番号45の塩基配列を有するプローブ、アデノウイルスのヘキソンタンパク質遺伝子を検出することが可能な配列番号46〜49の塩基配列を有するプローブ、ライノーウイルスA、B、Cの5’UTRを検出することが可能な配列番号50及び51の塩基配列を有するプローブ、ボカウイルスのヌクレオカプシドタンパク質(NP)遺伝子を検出することが可能な配列番号52の塩基配列を有するプローブを、通常の方法を用いてそれぞれ製作した(表2参照)。
実施例2−1:必要な溶液の準備
下記表3に示す試薬を準備した。これらは使用前に常温で放置し、解凍した。常温で30分以上放置しないことが好ましい。
鼻咽頭の吸引物或いはスワブ(swab)検体(NPS(Nasopharyngeal swabs)、NS(Nasla swabs)、TS(Throat swabs)、NA(Nasal aspirates))を使用した。
実施例2−2で準備された検体からRNA抽出キットを用いてRNAを抽出した。RT−PCR プレミックスが10μLずつ分注されている200μLのPCRチューブを、試料、陽性対照液及び陰性対照液を加えた個数の分を準備した。予め分注されて提供された各RT−PCR プレミックスチューブにRVPプライマー/プローブの混合液5μLと抽出した試料、陽性対照液または陰性対照液を5μLずつ添加した(表4参照)。
(1)各対照群別Ct値
対照群を対象として反応したときのCt値(threshold cycle:カットオフ値 を通過するサイクル数)は次のとおりであり(表6及び表7参照)、試料のCt値が各項目(FAM、HEX及びCY5)において全て37以下の場合に陽性と判定した(表6及び表7参照)。
各反応別にFAM、HEX、CY5波長のシグナル形成を確認し、下記表のとおり反応有効性と陽性、陰性を分析した(表8参照)。
Claims (6)
- (1)配列番号13及び14の塩基配列を有するプライマーペア、及び配列番号17及び18の塩基配列を有するプライマーペアを含むプライマーセット、並びに配列番号40及び42の塩基配列を有するプローブのセットの混合物、
(2)配列番号19及び20の塩基配列を有するプライマーペア、配列番号21及び22の塩基配列を有するプライマーペアを含むプライマーセット、並びに配列番号43及び44の塩基配列を有するプローブのセットの混合物、並びに
(3)配列番号25及び26の塩基配列を有するプライマーペア、配列番号27〜29からなる群から選択される塩基配列を有する正方向プライマーと、配列番号30及び31からなる群から選択される塩基配列を有する逆方向プライマーの組み合わせからなるプライマーペアを含むプライマーセット、並びに配列番号46〜51の塩基配列を有するプローブのセットの混合物、
からなる群から選ばれる混合物を含む、マルチプレックスリアルタイムPCRに好適な、呼吸器系ウイルスによる疾患の同時診断用組成物。 - (2)の前記混合物が、配列番号23及び24の塩基配列を有するプライマーペア及び配列番号45の塩基配列を有するプローブ、および/または(3)の前記混合物が、配列番号32及び33の塩基配列を有するプライマーペア及び配列番号52の塩基配列を有するプローブ、をさらに含む、請求項1に記載の同時診断用組成物。
- ホットスタートTaq DNAポリメラーゼ及び逆転写酵素をさらに含む、請求項1に記載の組成物。
- 内部コントロールとして、RNasePの増幅のための、配列番号15及び16の塩基配列を有するプライマーペアをさらに含む、請求項1に記載の組成物。
- 内部コントロールとして、RNasePを検出するための、配列番号41の塩基配列を有するプローブをさらに含む、請求項1に記載の組成物。
- 請求項1〜5のいずれか1項の組成物を含む、マルチプレックスリアルタイムPCRに好適な、呼吸器系ウイルスによる疾患の同時診断キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110014807A KR101939336B1 (ko) | 2011-02-18 | 2011-02-18 | 호흡기 바이러스 검출용 조성물 및 이를 포함하는 호흡기 바이러스 검출용 키트 |
KR10-2011-0014807 | 2011-02-18 | ||
PCT/KR2012/001262 WO2012112012A2 (ko) | 2011-02-18 | 2012-02-20 | 호흡기 바이러스로 인한 질환의 동시진단용 키트 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014511177A JP2014511177A (ja) | 2014-05-15 |
JP6329370B2 true JP6329370B2 (ja) | 2018-05-23 |
Family
ID=46673070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013554403A Active JP6329370B2 (ja) | 2011-02-18 | 2012-02-20 | 呼吸器系ウイルスによる疾患の同時診断キット |
Country Status (5)
Country | Link |
---|---|
US (1) | US10106860B2 (ja) |
EP (1) | EP2677038B1 (ja) |
JP (1) | JP6329370B2 (ja) |
KR (1) | KR101939336B1 (ja) |
WO (1) | WO2012112012A2 (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101821547B1 (ko) | 2015-07-29 | 2018-01-25 | 대한민국 | 호흡기 질환 원인체 검출용 조성물 |
CN108239676A (zh) * | 2016-12-23 | 2018-07-03 | 上海星耀医学科技发展有限公司 | 一种副流感病毒一步法荧光分型rt-pcr检测试剂盒 |
WO2018175883A1 (en) * | 2017-03-24 | 2018-09-27 | Gen-Probe Incorporated | Compositions and methods for detecting or quantifying parainfluenza virus |
KR101886274B1 (ko) * | 2017-05-08 | 2018-08-08 | (주)바이오니아 | 메르스 코로나 바이러스의 검출용 조성물 및 이를 포함하는 메르스 코로나바이러스 검출방법 및 키트 |
KR101857685B1 (ko) * | 2017-09-22 | 2018-05-14 | 주식회사 코젠바이오텍 | 코로나바이러스의 아형을 동시에 검출하기 위한 프라이머 및 프로브, 및 이를 이용한 코로나바이러스의 검출방법 |
KR101886272B1 (ko) * | 2017-11-30 | 2018-08-08 | (주)바이오니아 | 메르스 코로나 바이러스의 검출용 조성물 및 이를 포함하는 메르스 코로나바이러스 검출방법 및 키트 |
CN108504774B (zh) * | 2018-02-26 | 2021-12-14 | 宁波海尔施基因科技有限公司 | 一种检测鼻病毒分型和肠道病毒的方法 |
KR102040303B1 (ko) * | 2018-06-19 | 2019-11-04 | 국방과학연구소 | 생물학작용제 검출용 프라이머, 프로브, 이를 포함하는 키트 및 이를 이용한 검출 방법 |
KR102146113B1 (ko) * | 2018-11-22 | 2020-08-19 | 한국표준과학연구원 | 인간 알파코로나바이러스 전장유전체 증폭을 통한 진단키트 및 전장 유전체 서열 확인 방법 |
CN109487008B (zh) * | 2018-12-26 | 2022-03-29 | 中元汇吉生物技术股份有限公司 | 呼吸道病原体的多重pcr检测试剂盒、用途及其使用方法 |
CN110273025A (zh) * | 2019-06-19 | 2019-09-24 | 佛山科学技术学院 | 一种阿龙山病毒pcr检测引物组、试剂盒及应用 |
CN110331232B (zh) * | 2019-06-20 | 2022-07-05 | 广州达安基因股份有限公司 | 一种呼吸道病原体多重核酸检测试剂盒 |
CN110468234A (zh) * | 2019-08-09 | 2019-11-19 | 厦门安普利生物工程有限公司 | 用于19种人呼吸道病毒检测的多重荧光定量pcr试剂盒 |
CN110468238A (zh) * | 2019-09-11 | 2019-11-19 | 深圳市芯思微生物科技有限公司 | 一种恒温扩增检测甲型和乙型流感病毒的引物探针组、试剂盒及应用 |
CN111411172A (zh) * | 2020-02-28 | 2020-07-14 | 江苏硕世生物科技股份有限公司 | 一种同时检测人新型冠状病毒和甲型流感、乙型流感病毒的探针及引物组合物 |
CN111394514B (zh) * | 2020-03-30 | 2023-01-06 | 杭州千基生物科技有限公司 | 一种同时检测24种呼吸道病原菌量子点核酸检测试剂盒及方法 |
US20230257833A1 (en) * | 2020-07-14 | 2023-08-17 | Seegene, Inc. | Sampling kits and methods for detecting respiratory pathogens |
KR102526524B1 (ko) * | 2020-09-02 | 2023-04-27 | 한국표준과학연구원 | 전장유전체 증폭을 위한 인간 사스-코로나바이러스-2 범용 프라이머 세트 및 이를 이용한 진단 키트 |
US20220162600A1 (en) * | 2020-11-23 | 2022-05-26 | Zunyi Yang | Compositions for the Multiplexed Detection of Viruses |
CN112593013B (zh) * | 2020-12-29 | 2022-07-05 | 西北农林科技大学 | 牛副流感病毒和牛呼吸道合胞体病毒双重rpa检测试剂盒 |
CN113005228B (zh) * | 2021-04-06 | 2023-10-10 | 上海君远生物科技有限公司 | 一种同步检测多项呼吸道病原体的检测试剂盒及其检测方法 |
CN113073149A (zh) * | 2021-04-26 | 2021-07-06 | 济南国益生物科技有限公司 | 一种基于lfd-rma法检测人腺病毒的引物探针组 |
CN113430301B (zh) * | 2021-06-09 | 2024-01-02 | 上海伯杰医疗科技有限公司 | 一种呼吸道病原体检测用组合物、试剂盒及其应用 |
CN113817870B (zh) * | 2021-09-10 | 2023-12-22 | 宁波海尔施基因科技股份有限公司 | 同时检测七种呼吸道相关病毒的引物组合物及其应用 |
CN114262759B (zh) * | 2022-02-11 | 2024-02-27 | 重庆巴斯德生物医药科技有限公司 | 一种联合检测多种呼吸道病毒的pcr引物组及试剂盒 |
CN116287434B (zh) * | 2022-10-21 | 2024-03-26 | 深圳康美生物科技股份有限公司 | 一种呼吸道症候群病原体核酸检测试剂盒 |
CN116219075B (zh) * | 2023-03-15 | 2023-09-22 | 北京华瑞康源生物科技发展有限公司 | 可覆盖45种基因型合胞病毒的引物对、探针组合、检测方法及试剂盒 |
CN117144063B (zh) * | 2023-09-15 | 2024-04-19 | 果然基因科技(山东)股份有限公司 | 一种12种呼吸道病原体荧光pcr熔解曲线试剂盒 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6015664A (en) * | 1995-11-03 | 2000-01-18 | Mcw Research Foundation | Multiplex PCR assay using unequal primer concentrations to detect HPIV 1,2,3 and RSV A,B and influenza virus A, B |
US6110457A (en) * | 1995-12-08 | 2000-08-29 | St. Louis University | Live attenuated vaccines based on cp45 HPIV-3 strain and method to ensure attenuation in such vaccines |
AU2003294533A1 (en) * | 2002-12-19 | 2004-07-14 | Universite Laval | Molecular methods and compositions for detecting and quantifying respiratory viruses |
CA2522379C (en) * | 2003-04-10 | 2012-10-23 | Chiron Corporation | The severe acute respiratory syndrome coronavirus |
BRPI0413825A (pt) * | 2003-08-22 | 2006-10-24 | Birch Biomedical Res Llc | detecção molecular multialélica de coronavìrus associado com sars |
US8318423B2 (en) * | 2004-07-06 | 2012-11-27 | Focus Diagnostics, Inc. | Methods and compositions for detecting rhinoviruses |
ES2303395B1 (es) | 2004-12-24 | 2009-05-29 | Instituto De Salud Carlos Iii | Sondas y metodos para la deteccion e identificacion simultanea de multiples virus causantes de infecciones respiratorias en humanos. |
KR100738082B1 (ko) | 2004-12-24 | 2007-07-12 | 삼성전자주식회사 | 핵산 프라이머 세트, 핵산 프로브 세트 및 그들을 이용한호흡기 질환 바이러스의 검출방법 |
US20070087338A1 (en) * | 2005-10-17 | 2007-04-19 | Rangarajan Sampath | Compositions for use in identification of influenza viruses |
US20070092871A1 (en) * | 2005-10-20 | 2007-04-26 | Combimatrix Corporation | Microarray for pathogen identification |
KR100824414B1 (ko) * | 2005-11-11 | 2008-04-23 | 대한민국 | 호흡기바이러스 진단을 위한 단일튜브-멀티플렉스rt-pcr 방법 및 프라이머 |
US8110350B2 (en) | 2005-11-17 | 2012-02-07 | Karolinska Institutet Innovations Ab | Human Bocavirus and methods of diagnosis and treatment |
US20090124512A1 (en) | 2006-01-18 | 2009-05-14 | Regents Of The University Of Colorado | Dna array analysis as a diagnostic for current and emerging strains of influenza |
US8232058B2 (en) * | 2006-01-20 | 2012-07-31 | Lawrence Livermore National Security, Llc | Multiplex detection of respiratory pathogens |
US20080003565A1 (en) * | 2006-05-02 | 2008-01-03 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Viral nucleic acid microarray and method of use |
CA2653454A1 (en) | 2006-05-23 | 2007-11-29 | Molecular Detection, Inc. | Ambient temperature stable kits for molecular diagnostics |
US7972786B2 (en) * | 2006-07-07 | 2011-07-05 | Brandeis University | Detection and analysis of influenza virus |
WO2008016594A1 (en) * | 2006-07-31 | 2008-02-07 | The Trustees Of Columbia University In The City Of New York | Picornavirus and uses thereof |
EP2152871A4 (en) * | 2007-05-31 | 2011-01-05 | Becton Dickinson Co | SEQUENCES AND METHOD FOR DETECTING INFLUENZA VIRUS A AND INFLUENZA VIRUS B |
KR100909621B1 (ko) * | 2007-06-19 | 2009-07-29 | 대한민국 | 사람 보카바이러스의 절대 정량을 위한 실시간 pcr 분석방법 |
US20100279273A1 (en) * | 2007-07-17 | 2010-11-04 | Universite Laval | Nucleic acid sequences for the amplification and detection of respiratory viruses |
CN101812532A (zh) * | 2009-02-24 | 2010-08-25 | 江苏默乐生物科技有限公司 | 呼吸道合胞病毒、腺病毒、副流感病毒和流感病毒检测引物和探针 |
KR101055629B1 (ko) * | 2009-06-02 | 2011-08-09 | 대한민국 | 사람 코로나 바이러스(HCoV)-HKU1의 절대 정량을 위한 실시간 PCR 분석 방법 |
US10202617B2 (en) * | 2011-02-08 | 2019-02-12 | Temasek Life Sciences Laboratory Limited | Expression cassette for efficient surface display of antigenic proteins |
-
2011
- 2011-02-18 KR KR1020110014807A patent/KR101939336B1/ko active IP Right Grant
-
2012
- 2012-02-20 US US14/000,153 patent/US10106860B2/en active Active
- 2012-02-20 EP EP12747732.1A patent/EP2677038B1/en active Active
- 2012-02-20 JP JP2013554403A patent/JP6329370B2/ja active Active
- 2012-02-20 WO PCT/KR2012/001262 patent/WO2012112012A2/ko active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP2014511177A (ja) | 2014-05-15 |
US10106860B2 (en) | 2018-10-23 |
EP2677038B1 (en) | 2017-05-17 |
EP2677038A4 (en) | 2015-06-03 |
KR20120095256A (ko) | 2012-08-28 |
US20140127671A1 (en) | 2014-05-08 |
WO2012112012A3 (ko) | 2012-12-20 |
EP2677038A2 (en) | 2013-12-25 |
WO2012112012A2 (ko) | 2012-08-23 |
KR101939336B1 (ko) | 2019-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6329370B2 (ja) | 呼吸器系ウイルスによる疾患の同時診断キット | |
Mackay et al. | Molecular assays for detection of human metapneumovirus | |
US20080261198A1 (en) | Diagnostic Primers and Method for Detecting Avian Influenza Virus Subtype H5 and H5n1 | |
ES2439951T3 (es) | Detección y cuantificación multiplex de ácidos nucleicos microbianos controlada de forma interna | |
Alhamid et al. | SARS-CoV-2 detection methods: A comprehensive review | |
US20180265936A1 (en) | Compositions and methods for detection and discrimination of influenza viruses | |
Cannon et al. | A low density oligonucleotide microarray for the detection of viral and atypical bacterial respiratory pathogens | |
KR20230030639A (ko) | Sars-cov-2, 인플루엔자 및 rsv를 검출하는 방법 | |
Coiras et al. | Oligonucleotide array for simultaneous detection of respiratory viruses using a reverse‐line blot hybridization assay | |
CN113652505A (zh) | 检测新型冠状病毒及其voc-202012/01突变株的方法和试剂盒 | |
Mo et al. | Validation of specific quantitative real-time RT-PCR assay panel for Infectious Bronchitis using synthetic DNA standards and clinical specimens | |
US20230203603A1 (en) | Rt-pcr detection reagent for detecting novel coronavirus, kit and detection method thereof | |
US10329630B2 (en) | Compositions and methods for detection and discrimination of emerging influenza virus subtypes | |
KR20110028188A (ko) | 실시간 다중 역전사 중합효소 연쇄반응에 의한 일반 인플루엔자 a와 신종 인플루엔자의 동시 검출방법 | |
WO2006132601A1 (en) | Diagnostic primers and method for detecting avian influenza virus subtype h5 and h5n1 | |
CN102876813A (zh) | 一种检测禽流感病毒的实时荧光rt-hda试剂盒及引物 | |
KR102072110B1 (ko) | 호흡기 바이러스 검출용 조성물 및 이를 포함하는 호흡기 바이러스 검출용 키트 | |
US20180080091A1 (en) | Detection of influenza b viruses | |
EP3933052A1 (en) | Rapid detection kit for human pathogenic coronaviruses : betacoronavirus group b/c and sars-cov-2 | |
Kuriakose et al. | Detection of avian influenza viruses and differentiation of H5, H7, N1, and N2 subtypes using a multiplex microsphere assay | |
CN111172320A (zh) | 呼吸道合胞病毒f基因的检测引物、试剂盒及方法 | |
KR102072108B1 (ko) | 호흡기 바이러스 검출용 조성물 및 이를 포함하는 호흡기 바이러스 검출용 키트 | |
KR102072109B1 (ko) | 호흡기 바이러스 검출용 조성물 및 이를 포함하는 호흡기 바이러스 검출용 키트 | |
Malanoski et al. | Evolving gene targets and technology in influenza detection | |
RU2795939C2 (ru) | Набор реагентов для выявления РНК вируса SARS-CoV-2 методом прямой полимеразной цепной реакции в режиме реального времени |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150420 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150520 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150721 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151208 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160302 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160408 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160502 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160608 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160816 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161216 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170210 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20170421 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20170731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170731 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180205 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180420 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6329370 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |